About Biogen
Biogen is a company based in Cambridge (United States) founded in 1978 by Heinz, Phillip Allen Sharp, Walter Gilbert, and Charles Weissmann. It operates as a Direct-to-Consumer (D2C) and Professional Services. Biogen has raised $80 million across 2 funding rounds from investors including PRIMECAP. The company has 7,610 employees as of December 31, 2024. Biogen has completed 13 acquisitions, including Apellis Pharmaceuticals, Conforma and Convergence Pharma. Biogen offers products and services including Alzheimer's Disease Therapies, Multiple Sclerosis Treatments, and Spinal Muscular Atrophy Solutions. Biogen operates in a competitive market with competitors including Jazz Pharmaceuticals, Neurocrine, PTC Therapeutics, ADMA Biologics and Biohaven Pharmaceutical, among others.
- Headquarter Cambridge, United States
- Employees 7610 as on 31 Dec, 2024
- Founders Heinz, Phillip Allen Sharp, Walter Gilbert, Charles Weissmann
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biogen Inc.
-
Annual Revenue
$9.27 B (USD)-1.6as on Dec 31, 2024
-
Net Profit
$1.63 B (USD)40.57as on Dec 31, 2024
-
EBITDA
$2.8 B (USD)31.57as on Dec 31, 2024
-
Total Equity Funding
$80 M (USD)
in 2 rounds
-
Latest Funding Round
Not available
- Investors
-
Employee Count
7610
as on Dec 31, 2024
-
Investments & Acquisitions
Apellis Pharmaceuticals
& 12 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Biogen
Biogen is a publicly listed company on the NASDAQ with ticker symbol BIIB in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Biogen
Biogen offers a comprehensive portfolio of products and services, including Alzheimer's Disease Therapies, Multiple Sclerosis Treatments, and Spinal Muscular Atrophy Solutions.
Therapies for Alzheimer's disease are developed and provided.
Treatments for multiple sclerosis are researched and offered.
Solutions for spinal muscular atrophy are created and distributed.
People of Biogen
Unlock access to complete
Unlock access to complete
Software Development Team
228 people
Leadership Team
166 people
Senior Team
48 people
Data Analysis and Operations Team
41 people
Sales and Marketing
40 people
Product Management Team
38 people
Human Resources and Administration
38 people
Head Team
37 people
Unlock access to complete
Funding Insights of Biogen
Biogen has successfully raised a total of $80M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Biogen
Biogen has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include PRIMECAP.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Manages mutual funds through fundamental stock selection and long-term horizons.
|
Locked | Locked | Locked |
Investor details for Biogen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biogen
Biogen has strategically engaged in corporate development activities, having acquired 13 companies. Notable acquisitions include Apellis Pharmaceuticals, Conforma and Convergence Pharma.
Investment portfolio details for Biogen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Small molecule therapies for immunology unmet needs are developed.
|
Locked | Locked | 2023 | Locked | |
|
Precision medicines for autoimmune and inflammatory diseases are developed.
|
Locked | Locked | 2021 | Locked | |
|
Gene therapies for inherited retinal diseases are developed.
|
Locked | Locked | 2013 | Locked |
Complete acquisition details for Biogen
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Biogen
Detailed financials for Biogen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biogen Comparisons
Peer comparison for Biogen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Biogen
Biogen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Neurocrine, PTC Therapeutics, ADMA Biologics and Biohaven Pharmaceutical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
Detailed competitors of Biogen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biogen
Complete news archive for Biogen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biogen
Biogen was founded in 1978 and raised its 1st funding round 5 years after it was founded.
Biogen is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Christopher Viehbacher is the current CEO of Biogen.
Biogen is a funded company, having raised a total of $80M across 2 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Biogen is 7,610.
Annual revenue of Biogen is $9.27B as on Dec 31, 2024.
Biogen is focused on the research and development of innovative therapies for neurological and neurodegenerative diseases. Areas of expertise include Alzheimers disease, multiple sclerosis, and spinal muscular atrophy. Solutions are provided through clinical trials and early access programs. The company operates globally, addressing health equity and access. Sectors served include biotechnology and healthcare with a commitment to transformative medicines.
Biogen's top competitors include Jazz Pharmaceuticals, ADMA Biologics and PTC Therapeutics.
Biogen offers Alzheimer's Disease Therapies, Multiple Sclerosis Treatments, and Spinal Muscular Atrophy Solutions.
Yes, Biogen is publicly traded on NASDAQ under the ticker symbol BIIB.
Biogen has made 13 acquisitions, including Apellis Pharmaceuticals, Conforma, and Convergence Pharma.
Biogen has 1 investor. Key investors include PRIMECAP.
The ticker symbol of Biogen is BIIB on NASDAQ.